A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer

The goal of this clinical study is to compare the efficacy and safety of OT-101 in combination with mFOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) to mFOLFIRINOX alone in patients with advanced and unresectable or metastatic pancreatic cancer.

Trial Details

NCT ID
NCT06079346
Phase
PHASE2 / PHASE3
Sponsor
Oncotelic Inc.
Status
RECRUITING
Cancer Type
Pancreatic Ductal Adenocarcinoma Pancreatic Cancer
Interventions
  • OT-101
  • mFOLFIRINOX
Locations (sample)
  • Detroit, Michigan, United States|42.33143,-83.04575
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • A diagnosis of advanced and unresectable or metastatic pancreatic adenocarcinoma confirmed by:
  • Histopathology from primary tumor in pancreas, OR
  • Histopathology from a non-pancreatic lesion in the presence of a mass in the pancreas consistent with pancreatic adenocarcinoma or a medically docu…
  • Measurable disease per RECIST v.1.1

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Trials on Trialify →